Patent · US Active

Combination therapy with Axl inhibitor and immune checkpoint modulator or oncolytic virus

US11534440B2 · kind B2 · utility

0Cited by

2References

18Claims

0Family size

Assignee

BERGENBIO ASA · NO

Inventors

James Lorens · Otta, NO
Gro GAUSDAL · Bjørndalstræ, NO

Key dates

Filing date	Jan 9, 2020
Grant date	Dec 27, 2022
Priority date	—
Expiry date	Jan 9, 2040

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

An Axl inhibitor and one or more immune checkpoint (activity) modulators and/or one or more oncolytic viruses, for use in the prevention, treatment or management of cancer, wherein the Axl inhibitor and the one or more immune checkpoint (activity) modulators and/or the one or more oncolytic viruses are administered concurrently, separately or sequentially; compositions containing such components in combination; and methods of treating cancer in a patient by administering such components in combination.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.